CorMedix (CRMD) Scheduled to Post Quarterly Earnings on Thursday

CorMedix (NASDAQ:CRMD) is scheduled to release its earnings data before the market opens on Thursday, May 9th. Analysts expect CorMedix to post earnings of ($0.27) per share for the quarter.

CorMedix (NASDAQ:CRMD) last announced its quarterly earnings data on Tuesday, March 12th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.05). On average, analysts expect CorMedix to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

CorMedix Price Performance

CRMD traded down $0.04 during mid-day trading on Tuesday, hitting $5.85. The stock had a trading volume of 248,751 shares, compared to its average volume of 554,753. CorMedix has a 1-year low of $2.57 and a 1-year high of $7.00. The stock’s fifty day simple moving average is $4.53 and its 200-day simple moving average is $3.79. The firm has a market capitalization of $320.64 million, a price-to-earnings ratio of -6.41 and a beta of 1.79.

Insiders Place Their Bets

In other CorMedix news, CEO Joseph Todisco acquired 13,561 shares of the stock in a transaction that occurred on Wednesday, March 13th. The shares were acquired at an average cost of $3.74 per share, with a total value of $50,718.14. Following the transaction, the chief executive officer now owns 352,839 shares of the company’s stock, valued at approximately $1,319,617.86. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 4.60% of the company’s stock.

Wall Street Analysts Forecast Growth

CRMD has been the subject of a number of research reports. Royal Bank of Canada cut their target price on shares of CorMedix from $10.00 to $9.00 and set an “outperform” rating for the company in a research note on Wednesday, March 13th. JMP Securities reiterated a “market outperform” rating and set a $19.00 target price on shares of CorMedix in a research report on Tuesday, April 9th. Truist Financial lowered their price objective on shares of CorMedix from $18.00 to $14.00 and set a “buy” rating on the stock in a report on Wednesday, January 31st. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $10.00 target price on shares of CorMedix in a research note on Tuesday, April 9th.

About CorMedix

CorMedix Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.